Cell and Gene Therapy Manufacturing: An Emerging Frontier in Healthcare

The key drivers influencing the Cell and Gene Therapy Manufacturing Market expansion include its health benefits, including the treatment of blood cancers, lymphomas, leukemia, and solid tumors, and for the treatment of multiple myeloma.

Cell and gene therapy manufacturing services are a process of introducing cells or genes into the patients to treat a disease. The cells or genes can be sourced from the patient himself, or a donor. They are cultured during the production process, after which they are purified and packaged for delivery to the patient. The patient receives the cells or genes through injection or infusion.

Ask for PDF Brochure

In 2018, cancer was the second leading cause of death globally, accounting for over 9.6 million deaths, an average of one in six deaths. Cell and gene therapy treatment is widely used for treating various types of cancers which is escalating its demand consequently driving the cell and gene therapy manufacturing services.

A few of the recent developments in the cell and gene therapy manufacturing services market are:

• In August 2022, Catalent, Inc. announced its plans to acquire Metrics Contract Services for US$ 475 million from Mayne Pharma Group Limited. The acquired company is a full-service specialty Contract Development and Manufacturing Organization (CDMO) having a facility in North Carolina.
• In November 2021, Lonza announced that it has acquired the service unit from Exosomics, a provider of extracellular vesicle biotech. The agreement includes the Exosomics service team, service assets, and laboratories in Siena, Italy.
• In February 2021, Charles River Laboratories acquired a cell & gene therapy CDMO-Cognate BioServices. The objective of this acquisition was to increase its cell and gene therapy manufacturing capabilities.
• In June 2019, Century Therapeutics announced the launch of venture financing in the cell and gene therapy market with a total of US$ 250 million.